SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumors
Conditions
Advanced Solid Tumors, Ovarian Cancer, Breast Cancer
Trial Timeline
May 12, 2017 → Jun 24, 2020
NCT ID
NCT03134638About SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent) is a phase 1 stage product being developed by Syros Pharmaceuticals for Advanced Solid Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT03134638. Target conditions include Advanced Solid Tumors, Ovarian Cancer, Breast Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03134638 | Phase 1 | Terminated |
Competing Products
20 competing products in Advanced Solid Tumors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AK-105 | Akeso | Phase 1 | 32 |
| AFM24 + Atezolizumab 840 MG in 14 ML Injection | Affimed | Phase 1/2 | 33 |
| EXS21546 | Biotrial | Phase 1/2 | 33 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 52 |
| Pemetrexed + Erlotinib + Pemetrexed + Erlotinib | Eli Lilly | Phase 2 | 52 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 36 |
| pegfilgrastim + LY2523355 | Eli Lilly | Phase 1 | 33 |
| SON-1010 | Sonnet BioTherapeutics | Phase 1 | 28 |
| SON-1010 | Sonnet BioTherapeutics | Phase 1/2 | 36 |
| BT1718 | Bicycle Therapeutics | Phase 1/2 | 33 |
| Zentalis + Gemzar | Zentalis Pharmaceuticals | Phase 2 | 44 |
| IMC-18F1 | Eli Lilly | Phase 1 | 33 |
| Tadalafil + Gemcitabine | Eli Lilly | Phase 1 | 33 |
| OKI-179 | OnKure Therapeutics | Phase 1 | 25 |
| OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + Ribociclib | OnKure Therapeutics | Phase 1 | 25 |
| LY3499446 + Abemaciclib + Cetuximab + Erlotinib + Docetaxel | Eli Lilly | Phase 1/2 | 41 |
| LY3434172 | Eli Lilly | Phase 1 | 33 |
| ACR-2316 | Acrivon Therapeutics | Phase 1 | 25 |
| BBP-398 | LianBio | Phase 1 | 25 |
| LY3200882 + Pembrolizumab | Eli Lilly | Phase 1/2 | 41 |